Login to Your Account



Financings Roundup

Awaiting Data, BioMarin Pads Coffers with $249M Offering

By Marie Powers
Staff Writer

Friday, June 1, 2012
As it prepares for the readouts from a handful of clinical trials in the second half of the year, rare disease developer BioMarin Pharmaceutical Inc. turned to the markets to seek $248.8 million from an underwritten public offering of 6.5 million shares of common stock.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription